CMT2A is the most prevalent subtype among CMT2 patients, due almost exclusively to dominant mutations in the MFN2 gene that inhibit the fusion and motility of mitochondria.162 In a clinical setting, patients diagnosed with CMT2A frequently exhibit more severe symptoms and experience an earlier onset of the condition when compared to those with classic CMT.163 In addition, CMT2A manifests as peripheral neuropathy, progressive weakness of the muscles, impaired motor function, and may also affect the central nervous system (CNS), causing spinal cord or brain abnormalities. The gene discussed is MFN2; the disease is Charcot-Marie-Tooth disease.